Beacon introduces another new drug for Breast Cancer treatment.

Beacon introduces protein Tyrosine Kinase Inhibitor (TKI) Lapatinib under the brand name Lapanix (250 mg).

• Capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline,a taxane and trastuzumab.

• Letrozole for the treatment of postmenopausal women with hormone receptor positive metastaic breast cancer.

To know more visit our product website: www.lapanix.com